HomeCompareWEJOW vs ABBV

WEJOW vs ABBV: Dividend Comparison 2026

WEJOW yields 16666.67% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 WEJOW wins by $8601297707047409664.00M in total portfolio value
10 years
WEJOW
WEJOW
● Live price
16666.67%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8601297707047409664.00M
Annual income
$8,500,961,637,704,150,000,000,000.00
Full WEJOW calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — WEJOW vs ABBV

📍 WEJOW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodWEJOWABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, WEJOW + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
WEJOW pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

WEJOW
Annual income on $10K today (after 15% tax)
$1,416,666.67/yr
After 10yr DRIP, annual income (after tax)
$7,225,817,392,048,527,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, WEJOW beats the other by $7,225,817,392,048,527,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of WEJOW + ABBV for your $10,000?

WEJOW: 50%ABBV: 50%
100% ABBV50/50100% WEJOW
Portfolio after 10yr
$4300648853523704832.00M
Annual income
$4,250,480,818,852,075,000,000,000.00/yr
Blended yield
98.83%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

WEJOW
No analyst data
Altman Z
-54.7
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

WEJOW buys
0
ABBV buys
0
No recent congressional trades found for WEJOW or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricWEJOWABBV
Forward yield16666.67%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$8601297707047409664.00M$102.3K
Annual income after 10y$8,500,961,637,704,150,000,000,000.00$24,771.77
Total dividends collected$8594666089931243520.00M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: WEJOW vs ABBV ($10,000, DRIP)

YearWEJOW PortfolioWEJOW Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$1,677,367$1,666,666.67$11,550$430.00+$1.67MWEJOW
2$263,066,849$261,272,066.46$13,472$627.96+$263.05MWEJOW
3$38,576,943,838$38,295,462,310.00$15,906$926.08+$38576.93MWEJOW
4$5,289,656,888,585$5,248,379,558,677.81$19,071$1,382.55+$5289656.87MWEJOW
5$678,235,585,150,030$672,575,652,279,244.40$23,302$2,095.81+$678235585.13MWEJOW
6$81,321,145,183,775,540$80,595,433,107,665,010.00$29,150$3,237.93+$81321145183.75MWEJOW
7$9,118,299,079,523,715,000$9,031,285,454,177,076,000.00$37,536$5,121.41+$9118299079523.68MWEJOW
8$956,159,646,381,740,000,000$946,403,066,366,649,700,000.00$50,079$8,338.38+$956159646381740.00MWEJOW
9$93,772,027,423,605,150,000,000$92,748,936,601,976,690,000,000.00$69,753$14,065.80+$93772027423605152.00MWEJOW
10$8,601,297,707,047,409,000,000,000$8,500,961,637,704,150,000,000,000.00$102,337$24,771.77+$8601297707047409664.00MWEJOW

WEJOW vs ABBV: Complete Analysis 2026

WEJOWStock

Wejo Group Limited develops data marketplace and software-as-a-service (SaaS) solutions. It offers traffic management of the data marketplace and SaaS solutions. Its data exchange platform sources data directly from connected vehicles, using a range of sensors inside the vehicle integrated by the OEMs to ascertain vehicle status, vehicle health, dynamics, and location. The company was founded in 2014 and is based in Manchester, United Kingdom.

Full WEJOW Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this WEJOW vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

WEJOW vs SCHDWEJOW vs JEPIWEJOW vs OWEJOW vs KOWEJOW vs MAINWEJOW vs JNJWEJOW vs MRKWEJOW vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.